OCTOPLUS
Identification
OctoPlus is a drug delivery company specialized in the development of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. In addition, the group is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
- Net sales break down by source of income as follows: sales of services (97.9%), licensing revenues (1.9%) and subsidies (0.2%).
- Net sales are distributed geographically as follows: Europe (28.6%), North America (60.6%) and other (10.8%).
Operation
OFFER SHARES
Admission to listing and trading of 211,806 newly issued ordinary shares which form part of a private placement of 3,232,106 newly issued ordinary shares.
Octoplus NV has applied for admission of the remaining 211,806 Shares issued pursuant to the Private Placement to listing and trading on Euronext Amsterdam and expect that trading in these Shares on Euronext Amsterdam will commence on or about 8 March 2010(the “Listing Date”).